Rituximab for PTLD of the CNS: Is It a ‘No-Brainer’?

Publisher： Karger

E-ISSN： 2296-5262|31|12|650-651

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.12, 2008-11, pp. : 650-651

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A No-Brainer: Criticisms of Brain-Based Standards of Death

By Campbell Courtney S.  

The Journal of Medicine and Philosophy, Vol. 26, Iss. 5, 2001-10 ,pp. : 539-551

Oxford University Press

Access to resources Recommend Favorite

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 4, 2015-04 ,pp. : 1091-1100

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation

By Wolf T.   Kiderlen T.   Atta J.   Stephan C.   Kann G.   Brodt H.-R.   Brandts C.  

Infection, Vol. 42, Iss. 2, 2014-04 ,pp. : 445-447

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite